CUREVAC (CVAC)
$3.06
0.02 (0.65%)
CVAC Stock Quote Delayed 30 Minutes
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
We're really starting to get into earnings season with many of the biggest pre-market stock movers today connected to earnings news.
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
$3.20
Market Cap
680.93M
PE Ratio
-2.59
EPS
-1.18
Volume (Avg. Vol.)
507,252
Day's Range
$3.04 - $3.19
52-Week Range
$2.22 - $5.28
Dividend & Yield
N/A (N/A)
CVAC Stock Predictions, Articles, and CUREVAC News
CureVac Stock Is Just Another Part of a Bigger Story
With its Covid-19 vaccine candidate, CureVac stock soared after its IPO in August. But as Operation Warp Speed wraps up, investors may wonder if there's anything else.
No Need to Rush Into CureVac Stock After Massive IPO Pop
CVAC stock is one of many intriguing plays on a Covid-19 vaccine. But 300% above the IPO price, investors seemingly have better options.
Why Science and Economics Might Justify CureVac
Amid a sea of red ink in the Covid-19 vaccine space, CureVac stock has gone against the grain, printing some sizable gains. Can investors trust the momentum for CureVac?
Is CureVac a Buy on the Pullback? It Depends
Recent IPO and vaccine play CureVac stock could bounce back – but tread carefully. Much of the upside remains priced into shares.
Why CureVac Might Soar From Here
The coronavirus vaccine play is crowded and CureVac stock needs to win more deals to get noticed
Go Easy on CureVac Stock After Its Red-Hot Market Debut
CureVac stock has been hot since its IPO thanks to its coronavirus vaccine candidate. Here's why you should give CVAC a breather now.
CureVac Stock Has Been Hot Following Its Recent IPO
CureVac has extensive collaborations globally as well as a range of drug candidates. CureVac stock is a high-risk, high-return investment.
CureVac Stock Soars After Talks of Supplying Vaccines for the EU
CureVac stock soars after the company announced that it was in talks of supplying the vaccine to EU member states.
CureVac Is a Bet on a Safe and Effective Vaccine
CureVac is a bet on a winning Covid-19 vaccine that is effective and safe. Buying CureVac stock could produce a 27.5% annual compounded return over the next two years.
CureVac IPO: 13 Things for Potential CVAC Stock Investors to Know
The CureVac (CVAC) IPO is underway Friday and potential investors will want to keep an eye on the stock as it's seeing massive gains.
